---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-246964"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2025-10-22T23:59:59+00:00"
generated_at: "2026-05-17T02:44:40.705054+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nurix raises $250M in registered offering; shares priced at $10.21

## Summary
- Offering of 24,485,799 shares at $10.21/share; gross proceeds $250.0M, net ~$234.3M.
- Proceeds to fund clinical development of bexobrutideg in CLL and autoimmune indications.
- New and existing investors participate, including General Atlantic, Redmile, Braidwell, Deep Track, Perceptive Advisors.
- Offering expected to close October 23, 2025, subject to customary conditions.
- J.P. Morgan, Jefferies, Stifel act as joint book-running managers.

## SEC filing metadata
- accession: 0001193125-25-246964
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2025-10-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000119312525246964/0001193125-25-246964-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000119312525246964/d46133d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-246964
- JSON: https://secwatch.observer/filing/0001193125-25-246964.json
- Plain text: https://secwatch.observer/filing/0001193125-25-246964.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.